Q3 Earnings Alert: These are the most overvalued right nowSee Overvalued Stocks

Olympus CEO ousted after allegation of illegal drug purchase, shares slump

Published 10/27/2024, 08:38 PM
Updated 10/28/2024, 01:40 AM
© Reuters. FILE PHOTO: Olympus Corp incoming chief executive Stefan Kaufmann speaks during an interview with Reuters at the company's headquarters in Tokyo, Japan November 14, 2022.  REUTERS/Issei Kato/File Photo
7733
-

By Kiyoshi Takenaka

TOKYO (Reuters) -Japanese endoscope manufacturer Olympus Corp said on Monday that it has sacked Chief Executive Stefan Kaufmann after an allegation that he had purchased illegal drugs, sending its shares sliding 6%.

Kaufmann, a German national who only took the helm in April last year, had been tasked with expanding Olympus' medical equipment business after preceding CEO Yasuo Takeuchi steered the company through years of asset sales.

Takeuchi, 67 and an Olympus director, will take on CEO duties again for the time being, the company said.

"Upon receiving an allegation that Mr. Stefan Kaufmann had purchased illegal drugs ... Olympus, in consultation with outside legal counsel, immediately investigated the facts," the company said in a statement. It declined to comment on who made the allegation.

"Based on the results of the investigation, the Board of Directors unanimously determined that Mr. Stefan Kaufmann likely engaged in behaviours that were inconsistent with our global code of conduct, our core values, and our corporate culture."

It had asked for his resignation and Kaufmann complied, the statement said.

Reuters was unable to reach Kaufmann for comment.

Kaufmann, a 56-year-old veteran of more than 20 years at Olympus, took on the top job shortly after the company had received warning letters from the U.S. Food and Drug Administration about violations related to reporting requirements and quality system regulations for endoscopes and related accessories.

His two main priorities had been addressing those regulatory issues and growing the firm's core medtech business, according to a person who has worked with him and spoke on condition of anonymity.

Olympus was interested in deals in digital technology and robotics after selling off its camera, voice recorder and microscope businesses, Takeuchi told Reuters in a November 2022 joint interview with Kaufmann.

Olympus' 6% tumble on Monday put the company's shares on track for their biggest one-day fall in nearly three months. Since Kaufmann became CEO, the company's stock has climbed 16%, underperforming a 38% jump for the Nikkei 225.

Olympus has had its fair share of corporate scandals.

Thirteen years ago, its first foreign CEO Michael Woodford exposed accounting fraud related to overpaying for acquisitions to hide losses.

© Reuters. FILE PHOTO: Olympus Corp incoming chief executive Stefan Kaufmann speaks during an interview with Reuters at the company's headquarters in Tokyo, Japan November 14, 2022.  REUTERS/Issei Kato/File Photo

Woodford was fired soon after his appointment and lost a battle to take control of Olympus.

In 2015, Toyota Motor (NYSE:TM) executive Julie Hamp, an American, was arrested in Japan but later released on suspicion of illegally importing the painkiller Oxycodone into the country.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.